TD Cowen analyst Tyler Van Buren raised the firm’s price target on Travere Therapeutics (TVTX) to $40 from $30 and keeps a Buy rating on the shares. The firm said Q3 Filspari sales of $91MM (+26% Q/Q) led to an impressive 15% beat over consensus, underscoring strong demand, PSF pull-through, and persistence.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones
- Travere Therapeutics Reports Strong Q3 2025 Growth
- Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Travere Therapeutics reports Q3 EPS 29c, consensus (9c)